Article Text

Download PDFPDF

783 AKR1C3 – a potential prognostic biomarker for patients with endometrial carcinomas
  1. M Hojnik1,
  2. N Kenda Šuster2;3,
  3. Š Smrkolj2;3,
  4. S Frković Grazio4,
  5. I Verdenik2 and
  6. T Lanišnik Rižner1
  1. 1Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
  2. 2Division of Gynecology, Department of Obstetrics and Gynecology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
  3. 3Chair for Gynecology and Obstetrics, Medical Faculty, University of Ljubljana, Slovenia
  4. 4Division of Gynecology, Department of Pathology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia


Introduction/Background*Endometrial cancer is the most common gynecological cancer diagnosis in developed countries. Personalized treatments for these cancers depend on identification of prognostic and predictive biomarkers that allow stratification of patients.

The aldo-keto reductase (AKR) superfamily is getting attention in cancer research, because of AKR’s involvements in important biochemical processes. The enzyme AKR1C3 has many functions, which include production of prostaglandins, androgens, estrogens, and metabolism of different chemotherapeutics. AKR1C3 is thus implicated in the pathophysiology of different cancers.

Methodology In our study, we evaluated the immunohistochemical (IHC) staining of AKR1C3 in 123 paraffin-embedded samples of endometrial cancer and statistically examined possible correlations between expression of AKR1C3 and clinicopathological data (survival, stage of disease, lymphovascular invasion, menopausal status, parous status, smoking, use of hormone replacement therapy).

Result(s)*In endometrioid endometrial carcinoma, high AKR1C3 IHC expression correlated with better overall survival (p = 0.008) and with disease-free survival (p = 0.027). Significantly higher percentages of positive epithelial cells were seen for adjacent nonneoplastic endometrium compared to endometrioid endometrial cancer (p = 1 × 10−4).

Conclusion*These results demonstrate the potential use of AKR1C3 as an independent prognostic biomarker in endometrioid endometrial cancer. Clinically, this might mean that levels of AKR1C3 in endometrioid endometrial cancer could be determined preoperatively on diagnostic tissue samples to allow prediction of the cancer behavior and stratification of the patients for more personalized treatments.

Conflicts of Interest The authors declare no conflict of interest. Study was supported by the grants J3-2535 to T.L.R. from the Slovenian Research Agency.

Ethical Issues The study was approved by the National Medical Ethics Committee of the Republic of Slovenia (0120-701/2017-6).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.